Skip to content
Bending the Curve Trial by Trial
?

Platinum compoundsNever marketedDerivative of an earlier drugNeeds review

Satraplatin

Also known as JM216, JM-216, Orplatna

An oral platinum(IV) drug (JM216) tested mainly in castration-resistant prostate cancer. Its phase III trial improved progression-free but not overall survival; the European application was withdrawn in 2008 and a 2009 review noted no FDA-approved indication.

From discovery to approval

  1. 1993 · First described

    A 1993 preclinical report evaluated JM216, bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV), as an orally active platinum drug; later reviews call JM-216 satraplatin. It showed non-cross-resistance in three of six cisplatin-resistant cell-line pairs.[2][3][4][5]

  2. No approval is recorded on this site.

How it works

Taken by mouth. In the body it is expected to attach to DNA inside cells and stop them reproducing, so that tumour cells die.[1]

Where it came from and why

Reviews give the attractions as oral convenience, a milder toxicity profile than cisplatin, lack of cross-resistance with cisplatin and a possible role as a radiosensitiser.

Cancers

Family and partners

Derived from: Cisplatin

Worth knowing

  • In the phase III SPARC trial (950 patients), satraplatin plus prednisone reduced the risk of progression or death versus placebo plus prednisone (hazard ratio 0.67; 95% CI 0.57 to 0.77), with no difference in overall survival (hazard ratio 0.98; 95% CI 0.84 to 1.15).[6]
  • Pharmion notified the European Medicines Agency committee on 1 August 2008 that it wished to withdraw its application for Orplatna. The application was at day 180 of a procedure that normally takes up to 210 days, and the committee's provisional view was that it could not be approved because overall survival was not increased compared with placebo.[1]
  • A 2007 review calls satraplatin the first orally administered platinum drug to be evaluated in the clinic.[7]
  • A 2026 review lists satraplatin among platinum agents that entered clinical development without regulatory approval.[8]

References

  1. European Medicines Agency. Questions and answers on the withdrawal of the marketing application for Orplatna (satraplatin), EMEA/404511/2008, 25 September 2008. Source
  2. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res. 1993;53(11):2581-6. PubMed
  3. Bhargava A, Vaishampayan UN. Satraplatin: leading the new generation of oral platinum agents. Expert Opin Investig Drugs. 2009;18(11):1787-97. PubMedDOI
  4. Choy H, Park C, Yao M. Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res. 2008;14(6):1633-8. PubMedDOI
  5. Weiss RB, Christian MC. New cisplatin analogues in development. A review. Drugs. 1993;46(3):360-377. PubMedDOI
  6. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27(32):5431-8. PubMedDOI
  7. McKeage MJ. Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation. Drugs. 2007;67(6):859-69. PubMedDOI
  8. Kamusheva MS, Varbanov HP. Current clinical applications and future developments of platinum-based anticancer drugs. J Biol Inorg Chem. 2026;31(6):469-488. PubMedDOI